Wells Fargo raised the firm’s price target on Medline (MDLN) to $47 from $42 and keeps an Equal Weight rating on the shares. The firm raises its estimates following strong Q4 results and positive tariff developments. Guidance for 2026 appears to make conservative assumptions on same customer growth and could have upside if utilization doesn’t weaken materially, Wells adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN: